These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25156287)

  • 1. Biological activity studies of the novel glucagon-like peptide-1 derivative HJ07.
    Han J; Sun LD; Qian H; Huang WL
    Chin J Nat Med; 2014 Aug; 12(8):613-8. PubMed ID: 25156287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
    Han J; Sun L; Huang X; Li Z; Zhang C; Qian H; Huang W
    Br J Pharmacol; 2014 Dec; 171(23):5252-64. PubMed ID: 25039358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Human Glucagon-Like Peptide-1-albumin Recombinant Protein with Prolonged Hypoglycemic Effect Provides Efficient and Beneficial Control of Glucose Metabolism in Diabetic Mice.
    Li C; Yang M; Hou G; Liu S; Huan Y; Yu D; Sun S; Liu Q; Yan S; Shen Z
    Biol Pharm Bull; 2017 Sep; 40(9):1399-1408. PubMed ID: 28626167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological characterization and antidiabetic activity of a long-acting glucagon-like peptide-1 analogue conjugated to an antithrombin III-binding pentasaccharide.
    Patterson S; de Kort M; Irwin N; Moffett RC; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    Diabetes Obes Metab; 2015 Aug; 17(8):760-70. PubMed ID: 25929155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta).
    Young AA; Gedulin BR; Bhavsar S; Bodkin N; Jodka C; Hansen B; Denaro M
    Diabetes; 1999 May; 48(5):1026-34. PubMed ID: 10331407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes.
    Irwin N; Patterson S; de Kort M; Moffett RC; Wisse JA; Dokter WH; Bos ES; Miltenburg AM; Flatt PR
    ChemMedChem; 2015 Aug; 10(8):1424-34. PubMed ID: 26059252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.
    Madsbad S; Kielgast U; Asmar M; Deacon CF; Torekov SS; Holst JJ
    Diabetes Obes Metab; 2011 May; 13(5):394-407. PubMed ID: 21208359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term metabolic benefits of exenatide in mice are mediated solely via the known glucagon-like peptide 1 receptor.
    Tatarkiewicz K; Sablan EJ; Polizzi CJ; Villescaz C; Parkes DG
    Am J Physiol Regul Integr Comp Physiol; 2014 Apr; 306(7):R490-8. PubMed ID: 24477544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
    Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
    Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
    Holst JJ; Seino Y
    Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
    Guo XH
    Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological activity of novel dicoumarol glucagon-like peptide 1 conjugates.
    Han J; Sun L; Chu Y; Li Z; Huang D; Zhu X; Qian H; Huang W
    J Med Chem; 2013 Dec; 56(24):9955-68. PubMed ID: 24308627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo.
    Scott DA; Boye KS; Timlin L; Clark JF; Best JH
    Diabetes Obes Metab; 2013 Mar; 15(3):213-23. PubMed ID: 22958381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of insulin secretion and improvement of glucose intolerance by combining a novel G protein-coupled receptor 40 agonist DS-1558 with glucagon-like peptide-1 receptor agonists.
    Nakashima R; Yano T; Ogawa J; Tanaka N; Toda N; Yoshida M; Takano R; Inoue M; Honda T; Kume S; Matsumoto K
    Eur J Pharmacol; 2014 Aug; 737():194-201. PubMed ID: 24858371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.